Huntington’s disease affects not only movement, but also impairs a person’s ability to communicate. Studies have shown that 78 to 93 percent of patients with Huntington’s experience speech difficulties. Communication issues are more common in the later stages of the disease, although they also can be seen…

The hallmark of Huntington’s disease is difficulty with both involuntary movement, such as reflexes, and voluntary movement, such as walking. An example of an involuntary movement problem is akathisia, or restlessness. This is difficulty maintaining one position, or engaging in constant movement. Another is dystonia, muscle spasms…

SRX246 is an investigational medicine being developed by Azevan Pharmaceuticals to potentially treat neuropsychiatric symptoms in Huntington’s disease and other neurodegenerative disorders like Alzheimer’s disease, intermittent explosive disorder, and post-traumatic stress disorder. How SRX246 works SRX246 is a medicine that blocks a receptor in…

Scientists have yet to develop a cure for Huntington’s disease or a treatment that can stop its progression. But there are treatments that can help patients manage their symptoms, which include movement, cognitive, and psychiatric problems. And researchers continue to work on more effective treatments for the disease. Treatment for movement…

Last updated Sept. 12, 2023, by Marta Figueiredo, PhD  Fact-checked by Inês Martins, PhD What is Austedo for Huntington’s disease? Austedo (deutetrabenazine) is an approved oral therapy used to treat adults with chorea, or involuntary and uncontrolled movements, associated with Huntington’s disease. It is also…